Philip Ferrone, MD
Ophthalmology · Great Neck, NYNPI 1164535472
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $105,181 of the $155,457 with a category attached, or 67.7%. 26 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 36.6% of the total. 2025 is the largest year on record at $54,780, 2.3 times the $23,355 reported in 2019. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $485.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$57K
- Regeneron Healthcare Solutions, Inc.$23K
- Alcon$19K
- Genentech, Inc.$13K
- Regeneron$12K
- Novartis$9K
- plus $23K from 20 others
Across 1,777 payments — averaging $3154.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.1M
- Regeneron$2.1M
- Bayer$900K
- Apellis Pharmaceuticals, Inc.$255K
- Eyepoint US, Inc.$180K
- F. Hoffmann-la Roche AG$6K
What the payments were for
- Consulting fees$105,18168%
- Speaking & faculty fees$15,82210%
- Travel & lodging$21,14314%
- Food & beverage$13,2949%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 56 | $56,857 |
| Regeneron Healthcare Solutions, Inc. | 63 | $22,955 |
| Alcon | 13 | $19,110 |
| Genentech, Inc. | 30 | $13,392 |
| Regeneron | 10 | $11,569 |
| Novartis | 12 | $8,526 |
| F. Hoffmann-la Roche AG | 3 | $7,834 |
| Genentech USA, Inc. | 71 | $3,825 |
| Carl Zeiss Meditec, Inc. | 3 | $3,820 |
| AbbVie(2 entities) | 20 | $3,090 |
| Harrow Eye, LLC | 3 | $2,971 |
| Coherus Oncology, Inc. | 8 | $388 |
| Sandoz | 6 | $179 |
| Heidelberg Engineering, Inc. | 3 | $153 |
| Dompe US, Inc. | 1 | $120 |
| Aerie Pharmaceuticals, Inc. | 1 | $119 |
| ASD Specialty Healthcare, LLC | 1 | $105 |
| Biogen | 4 | $86 |
| Alimera Sciences, Inc. | 3 | $80 |
| Ocular Therapeutix, Inc. | 1 | $65 |
| Oculus Surgical Inc. | 2 | $61 |
| Astellas Pharma US Inc | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $34 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Eyepoint US, Inc. | 1 | $26 |
| Carl Zeiss Meditec AG | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$34,203
- EYLEA HD$25,536
- Unity$17,139
- Constellation$15,139
- Non-Covered Product$9,537
- BEOVU$8,272
- EYLEA$7,968
- VABYSMO$7,816
- Lucentis$5,838
- FORUM$3,750
- TRIESENCE$2,947
- FORUM Glaucoma Workplace$2,250
- Humphrey HFA$2,250
- IOLMaster 700$2,250
- NGENUITY$1,014
- FINESSE SHARKSKIN$1,014
- OZURDEX$750
- SUSVIMO$618
- Alcon Greishaber Finesse$403
- Cimerli$152
How this compares
$155,457 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $11,846 |
| Prednisolone Acetate | 133 | $6,678 |
| Travoprost | 33 | $5,389 |
| IlevroNepafenac | 12 | $5,123 |
| Bromfenac Sodium | 23 | $4,698 |
| Eplerenone | 18 | $1,866 |
| Ofloxacin | 58 | $1,153 |
| Ketorolac Tromethamine | 28 | $953 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $661 |
| Latanoprost | 71 | $567 |
| Timolol Maleate | 19 | $230 |
| Dorzolamide Hcl | 14 | $164 |
| Doxycycline Hyclate | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $3,090 | $11,84614 claims |
| NovartisIlevro | $8,526 | $5,12312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Great Neck
- Jonathan JonischGreat Neck$726K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.